PRME · Health care(biological products, (no diagnostic substances)) · 7 years of annual accounts filed with the SEC · latest fiscal year ended 2025-12-31
Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›
Prime Medicine, Inc. reported revenue of $4.6 million in fiscal 2025. On the accounting screens, it passes 3 of 7 Piotroski tests, its Altman Z'' of -9.21 is in the distress zone and its Beneish M-score is below the -1.78 line; 2 of the six cross-checks between its statements fire.
Revenue, fiscal 20254.6M
Operating margin-4498.1%gross margin —
Return on invested capital—
Free cash flow after stock pay-196.4M-4239.3% of revenue
Net debt ÷ EBITDA—net debt —
Piotroski F-score3/7tests of improvement passed
Share counts are in today's shares. The SEC's filings restate only recent years after a split, so these jumps were read as splits and the older years scaled to match — otherwise per-share figures would compare different units:
5-for-1 before fiscal 2021.
Is it growing?
Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.
RevenueOperating income
-300.0M-200.0M-100.0M0100.0M
2019
2020Revenue 5.2MOperating income -932,000
2021Revenue 0Operating income -84.5M
2022Revenue 0Operating income -116.5M
2023Revenue 0Operating income -204.8M
2024Revenue 3.0MOperating income -202.5M
2025Revenue 4.6MOperating income -208.3M
2019202020212022202320242025
Compound growth a year
3 yrs
5 yrs
6 yrs
Revenue
—
-2.3%
—
Shares
+63.7%
+62.3%
—
Falling shares are buybacks: each remaining share owns more of the company.
Does it earn more than its capital costs?
Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.
Needs a cost of capital, which comes from the valuation below.
Return on equity
-166.4%
Return on assets
-58.7%
Asset turnover
0.01×
Research & development
3468.0% of revenue
Overheads (SG&A)
1130.1% of revenue
Is the profit cash, and where does the cash go?
Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.
Net incomeFree cash flowAfter stock-based pay
-300.0M-200.0M-100.0M0
2019
2020Net income -3.4MFree cash flow -6.2MAfter stock-based pay -6.6M
2021Net income -165.4MFree cash flow -38.2MAfter stock-based pay -40.0M
2022Net income -121.8MFree cash flow -147.9MAfter stock-based pay -154.4M
2023Net income -198.1MFree cash flow -174.1MAfter stock-based pay -188.0M
2024Net income -195.9MFree cash flow -130.2MAfter stock-based pay -156.2M
2025Net income -201.1MFree cash flow -167.1MAfter stock-based pay -196.4M
2019202020212022202320242025
Per share
Earnings per shareFree cash flow per shareDividend per share
$-15.00$-10.00$-5.00$0.00
2019
2020Earnings per share $-0.26Free cash flow per share $-0.47
2021Earnings per share $-12.75Free cash flow per share $-2.95
2022Earnings per share $-3.59Free cash flow per share $-4.36
2023Earnings per share $-2.18Free cash flow per share $-1.91
2024Earnings per share $-1.65Free cash flow per share $-1.10
2025Earnings per share $-1.35Free cash flow per share $-1.12
2019202020212022202320242025
Shares outstanding
Diluted shares
050.0M100.0M150.0M
2019
2020Diluted shares 13.2M
2021Diluted shares 13.0M
2022Diluted shares 33.9M
2023Diluted shares 91.0M
2024Diluted shares 118.6M
2025Diluted shares 148.8M
2019202020212022202320242025
How strong is the balance sheet?
Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.
Net debt ÷ EBITDA
—
Interest coverage
— operating income ÷ interest
Current ratio
4.84 current assets ÷ current liabilities
Cash conversion cycle
—
Three classic screens of the accounts
Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.
Piotroski F-score
Is the business improving? Nine yes-or-no tests, this year against last.
3of 7 tests passed
✕ProfitableReturn on assets above zerofailed
✕Cash from operationsOperating cash flow above zerofailed
✓Profitability improvedReturn on assets higher than a year beforepassed
✓Profit backed by cashOperating cash flow above net income (low accruals)passed
–Less long-term debtLong-term debt as a share of assets fell — not reportedno data
✕More liquidCurrent ratio higher than a year beforefailed
✕No new sharesShare count did not growfailed
–Better gross marginGross margin higher than a year before — not reportedno data
✓Sells more per assetAsset turnover higher than a year beforepassed
Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.
Altman Z''-score
Does the balance sheet look like those of companies that went bankrupt?
-9.21distress zone
1.12.6
Working capital ÷ assets 0.42 × 6.56+2.75
Retained earnings ÷ assets -2.59 × 3.26-8.45
Operating income ÷ assets -0.61 × 6.72-4.09
Equity ÷ liabilities 0.54 × 1.05+0.57
Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.
Beneish M-score
Do the accounts resemble those of companies that manipulated their earnings?
-2.03below the -1.78 line
-1.78
Receivables vs sales 1.00 (not reported, set to 1)+0.92
Gross margin slipping 1.00 (not reported, set to 1)+0.53
Soft assets 2.00+0.81
Sales growth 1.55+1.39
Slower depreciation 0.76+0.09
Overheads vs sales 0.67-0.12
Profit not in cash -0.11-0.53
Leverage rising 0.86-0.28
Where it misleads: fast growth and acquisitions. Sales growth carries a heavy weight, so a company growing 50% a year scores like a suspect without having done anything. It is a screen from a 1999 study, not an accusation.
Where the statements disagree
Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.
Reported profit comfortably exceeds the cash generated (-201M against -163M).
Benign
Growth consuming working capital, or the seasonality of the year-end.
Worrying
Profit held up by accounting entries that do not turn into money.
Capital spending (5M) is well below depreciation (7M).
Benign
Mature assets, or a business that has become less capital-intensive.
Worrying
Under-investing: today's profit is being held up by consuming tomorrow's capacity.
What is it worth, under which assumptions?
A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.
The SEC accounts lack the lines needed for revenue, free cash flow or the share count, so there is no DCF for this company.
What it has filed lately
The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.
From the Form 13F of the 28 institutions followed on this site, as of the end of their last reported quarter. A 13F is filed up to 45 days later and shows only long positions in US-listed shares.
Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.
